Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

Convertible bonds 13 522 13 522 Provisions for risks 157 443 LT portion of capital lease obligations 0 Long-term debt less current portion 271 210 Long-term portion of deferred income 359 243 Total long-term liabilities 630 453 Current portion of long-term debt 920 920 Current portion of capital lease obligations 105 124 Accounts payable 1 096 2 070 Accrued liabilities 1 566 1 425 Deferred income short-term 1 527 1 150 Total short-term liabilities 5 214 5 690 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 37 589 29 847 EXONHIT THERAPEUTICS S.A. CONSOLIDATED CASH FLOW STATEMENT (in thousands of euros) Fiscal year ending Dec.31, Dec. 31, 2007 2008 OPERATING ACTIVITIES Net loss (7 340) (8 925) Depreciation and amortization of property & equipment 466 327 Depreciation of intangible assets 70 134 Retirement liability provision and other (11) 286 Capitalized interests on convertible bonds - - Gain (loss) on sales (37) - Increase (decrease) in cash from: Inventory
'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 17, 2011 Executives from NineSigma , Inc., the ... have written chapters on crucial elements of open innovation for ... Leading Experts. This bestselling book offers ... new solutions and capabilities outside of their organization and clearly ...
... and Ghent University have shown that a defective gene ... often-crippling inflammation of the joints that afflicts about 1% ... mechanism of the disease was largely unclear. In the ... demonstrate that a cell-specific defect in the expression of ...
... TARRYTOWN, N.Y., Aug. 16, 2011 Regeneron Pharmaceuticals, Inc. ... has received notification from the U.S. Food and Drug ... date to complete the priority review of the EYLEA ... age-related macular degeneration (wet AMD) to November 18, 2011, ...
Cached Biology Technology:From Leadership to Legal Issues, NineSigma Shares Best Practices in an Authoritative Guide to Open Innovation and CrowdSourcing 2Defect in A20 gene expression causes rheumatoid arthritis 2Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 2Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 3Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... , WASHINGTON, D.C., Dec. 15, 2011 Austen BioInnovation ... Drug Administration (FDA) have entered into a ground-breaking collaboration ... and effective use of biomaterials in medical devices. ... of Understanding that will allow the FDA to draw ...
... study has identified a gene mutation that researchers estimate dates ... disease mutation yet discovered. , Researchers with the Ohio State ... and Richard J. Solove Research Institute led the study and ... 13,600 years ago. Only a mutation seen in cystic fibrosis ...
... fetal exposure to carcinogens can vary substantially, a recent study ... depending on the stage of pregnancy when the fetus is ... in which toxic damage early in life can later manifest ... was done by scientists in the Linus Pauling Institute at ...
Cached Biology News:FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2Scientists discover second-oldest gene mutation 2Cancer from fetal exposure to carcinogens depends on dose, timing 2
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: